{"id":52486,"date":"2023-01-03T18:02:27","date_gmt":"2023-01-03T17:02:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/"},"modified":"2023-01-03T18:02:27","modified_gmt":"2023-01-03T17:02:27","slug":"poxel-announces-its-financial-calendar-for-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/","title":{"rendered":"Poxel Announces its Financial Calendar for 2023"},"content":{"rendered":"
\n

LYON, France–(BUSINESS WIRE)–POXEL SA<\/a> (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023.\n<\/p>\n

<\/a><\/p>\n\n\n\n\n\n\n\n\n\n
\n

\nEvent<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

\nDate*<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2022 Fourth Quarter Financial Update\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

\nFebruary 15, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2022 Annual Results\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

\nMarch 22, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2023 First Quarter Financial Update\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

\nMay 17, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2023 Second Quarter Financial Update\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

\nAugust 30, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2023 First Half Results\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

\nSeptember 13, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2023 Third Quarter Financial Update\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n\n

\nNovember 8, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n* Subject to modification.<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAll corporate information on Poxel, including financial statements, press releases and corporate presentations, is available on the Investors<\/a> page of the Company\u2019s website.\n<\/p>\n

\nAbout Poxel SA<\/b>\n<\/p>\n

\nPoxel is a clinical stage biopharmaceutical company<\/b> developing innovative treatments for chronic serious diseases with metabolic pathophysiology<\/b>, including non-alcoholic steatohepatitis (NASH)<\/b> and rare disorders. For the treatment of NASH, PXL065<\/b> (deuterium-stabilized R<\/i>-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.\n<\/p>\n

\nFor more information, please visit: www.poxelpharma.com<\/a>\n<\/p>\n

\nAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company\u2019s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould\u201d and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company\u2019s control that could cause the Company\u2019s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nContacts – Investor relations \/ Media<\/b>\n<\/p>\n

\nAur\u00e9lie Bozza
\n
Investor Relations & Communication Senior Director
\n
aurelie.bozza@poxelpharma.com<\/a>
+33 6 99 81 08 36\n<\/p>\n

\nElizabeth Woo
\n
Senior Vice President, Investor Relations & Communication
\n
elizabeth.woo@poxelpharma.com<\/a>\n<\/p>\n

\nNewCap
\n
Emmanuel Huynh or Arthur Rouill\u00e9
\n
poxel@newcap.eu<\/a>
+33 1 44 71 94 94\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023. Event Date* 2022 Fourth Quarter Financial Update February 15, 2023 2022 Annual … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52486","6":"format-standard","7":"category-industry"},"yoast_head":"\nPoxel Announces its Financial Calendar for 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Announces its Financial Calendar for 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023. Event Date* 2022 Fourth Quarter Financial Update February 15, 2023 2022 Annual ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T17:02:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230103005482\/en\/729413\/21\/Logo_Without_Background.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Poxel Announces its Financial Calendar for 2023\",\"datePublished\":\"2023-01-03T17:02:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/\"},\"wordCount\":439,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005482\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/\",\"name\":\"Poxel Announces its Financial Calendar for 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005482\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"datePublished\":\"2023-01-03T17:02:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005482\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005482\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-its-financial-calendar-for-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Announces its Financial Calendar for 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Announces its Financial Calendar for 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Announces its Financial Calendar for 2023 - Pharma Trend","og_description":"LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023. Event Date* 2022 Fourth Quarter Financial Update February 15, 2023 2022 Annual ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-03T17:02:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230103005482\/en\/729413\/21\/Logo_Without_Background.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Poxel Announces its Financial Calendar for 2023","datePublished":"2023-01-03T17:02:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/"},"wordCount":439,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005482\/en\/729413\/21\/Logo_Without_Background.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/","url":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/","name":"Poxel Announces its Financial Calendar for 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005482\/en\/729413\/21\/Logo_Without_Background.jpg","datePublished":"2023-01-03T17:02:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230103005482\/en\/729413\/21\/Logo_Without_Background.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230103005482\/en\/729413\/21\/Logo_Without_Background.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-its-financial-calendar-for-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel Announces its Financial Calendar for 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52486"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52486\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}